University of Leeds Featured PhD Programmes
Engineering and Physical Sciences Research Council Featured PhD Programmes
University of Kent Featured PhD Programmes
University of Edinburgh Featured PhD Programmes
University College London Featured PhD Programmes
"breast"×
10 miles

breast PhD Projects, Programs & Scholarships

We have 57 breast PhD Projects, Programs & Scholarships

  • "breast" ×
  • clear all
Order by 
Showing 1 to 10 of 57
  Finding a therapy for triple negative breast cancer patients
  Dr K. Britt
Applications accepted all year round
Triple negative breast cancers are a poor prognosis breast cancer with limited therapeutic options as they do not express estrogen receptors, progesterone receptors or Her2.
  Precision profiling the breast cancer microenvironment
  Prof V Speirs, Dr R Abu Eid
Application Deadline: 29 March 2019
The cancer microenvironment contains many different cell types, including various subsets of immune cells and cancer-associated fibroblasts, which support cancer growth.
  Investigating how platelet-derived ncRNAs are altering the genetics of breast cancer cells
  Research Group: Institute of Cancer Therapeutics
  Dr J Boyne, Prof P Loadman
Applications accepted all year round
Platelet-derived microparticles (PMPs) are capable of delivering non-coding RNAs (ncRNAs) to cells that modulate gene expression.
  Exploring mechanisms of resistance to anti-angiogenic therapy in breast cancer
  Dr C Kanthou, Prof N Brown
Applications accepted all year round
Vascular endothelial growth factor (VEGF) is a potent angiogenesis inducer and is often overexpressed in cancer. Circulating levels of VEGF as well as tumour microvessel density are of prognostic value in breast cancer.
  Ran GTPase as a potential novel therapeutic target in EMT transdifferentiation and breast cancer stem cell (BCSC) survival during metastatic development
  Research Group: Institute of Cancer Therapeutics
  Prof R Morgan, Prof M El-Tanani, Dr M Isreb, Dr M Najafzadeh
Applications accepted all year round
Breast cancer is the leading cause of cancer death in women worldwide. Accumulating evidence suggests that local disease recurrence and metastatic lesions, the major causes of patient mortality, are due to a subset of aggressive cells termed cancer stem cells (CSCs).
  Characterizing the in vivo functions of P-Rex1 in breast development and tumourigenesis
  Dr A Ucar, Prof K R Brennan, Dr A Malliri
Applications accepted all year round
Breast cancer is the most common cancer in the UK with a lifetime risk of 1-in-8 for women and accounts for 12,000 deaths annually.
  Risk and resilience factors for psychosocial outcomes following breast reconstruction following breast cancer
  Prof B Grunfeld
Applications accepted all year round
There are mixed psychosocial outcomes following breast reconstruction; there are variations in self-reported mood, fear of recurrence, satisfaction with the reconstruction and body image concerns.
  Characterizing the heterogeneity of stem cells in the normal breast and breast tumours
  Dr A Ucar, Prof K R Brennan
Applications accepted all year round
Tissue-restricted stem cells are crucial in supporting the development and maintenance of normal tissues. This is also true for tumours, as only a small population of tumour cells, which are known as cancer stem cells, have the unique stemness features and tumour-initiating capacity.
  MRC Precision Medicine DTP: Molecular pathology data science studies of breast cancer
  Dr J Figueroa, Dr A Sims, Assoc Prof N Tobin
Application Deadline: 8 April 2019
BACKGROUND. Datasets linked to molecular phenotypes are desperately needed to provide academia and industry the real-world evidence needed for discovery, validation and implementation of new biomarkers for improved cancer outcomes.
  Functional significance of IL-1B in breast cancer bone metastases
  Dr P Ottewell
Applications accepted all year round
Breast cancer is the most frequently diagnosed cancer and leading cause of death in women worldwide. Up to 75% of patients with advanced breast cancer develop bone metastases and patients with this condition have a median survival of around 2-3 years.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.